Completed
An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer - CA209-9KD
Aggiornato:
8 gennaio, 2026
|
ClinicalTrials.gov
Sintesi in un linguaggio semplice